Articles by Ray Dogum

1. 2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics 6/10/2026

   Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.

2. 2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore 6/10/2026

   Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development. 

3. 2026 Nucleate Boston Activator Cohort Interview: Anna Kazatskaya — Fervid Therapeutics, previously Antozero 6/10/2026

   Anna Kazatskaya, CEO of Fervid Therapeutics is developing a novel peptide to treat pediatric epilepsy by increasing inhibitory synapses, backed by mouse data and a planned $2M pre-seed raise.

4. 2026 Nucleate Boston Activator Cohort Interview: Michael Cronce — Omni Therapeutics 6/9/2026

   Omni Therapeutics is developing first-in-class nucleotides from a novel immune metabolite, using Nucleate support to advance colorectal cancer programs.

5. A New De Novo Protein Design Platform For GPCR Drug Discovery 6/9/2026

   Skape Bio and UW created an AI-driven platform to design miniproteins that modulate GPCRs in living cells, opening new paths for biologic drug discovery.

6. Advancing Spatial Multiomics for Discovery: From Promise to Practice 6/5/2026

   Spatial multiomics offers extraordinary biological insight, but high costs, tissue bottlenecks, and unclear clinical relevance still limit its reach.

7. Discovery Dialogues: Winston Haynes, VP, Computational Sciences and Engineering, LabGenius Tx 6/5/2026

   DDO interviewed Winston Haynes, VP, computational sciences and engineering, LabGenius Tx, on their T-cell engagers platform, including its lead candidate LGTX-101, a Nectin-4 CD3 molecule showing strong preclinical efficacy.

8. Discovery Dialogues: Stef van Grieken, CEO, Cradle Bio 6/5/2026

   DDO caught up with Stef van Grieken, CEO of Cradle Bio, which uses AI to speed protein design, putting tools in scientists’ hands. Gains in lead optimization are clear, but safety CMC and tough targets remain key challenges.

9. Discovery Dialogues: Helen Bright, Ph.D., CSO of Centauri Tx 6/4/2026

   At PEGS Boston, Helen Bright, PhD explained how Centauri’s CTX187 harnesses innate immunity to fight resistant gram-negative infections and support better outcomes.

10. Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort 6/3/2026

    Nucleate Boston’s 2026 Activator shows how mentorship, structure, and community can help promising young scientists become credible biotech founders.